Cell Point (CELLPOINT)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Revenue growth of 15.26% shows the retail operations are still expanding.
• Latest quarter sales of ₹177 Cr against a ₹28 Cr market cap gives significant revenue scale if margins ever recover.
• ROCE of 4.77% is positive, though low, and the stock is above its 52-week low of ₹11.70.
• Small absolute market cap means modest profit improvements could have a meaningful per-share impact.

Concerns

• Latest quarter net profit is ₹0 Cr and trailing profit growth is -13.64%, indicating severe margin compression.
• P/E of 33.14 is expensive given falling profits and zero current-quarter earnings.
• Piotroski F-Score of 4/9 and PEG of 2.17 suggest weak financial health and poor growth value.
• No dividend means shareholders get no income while waiting for an uncertain recovery.

AI Analysis

Cell Point strikes me as a business that must be judged on margins, not sales. Retail is intensely competitive, and I see no clear moat from cost advantage, brand loyalty, or pricing power. The latest quarter shows ₹177 Cr of sales but ₹0 Cr of net profit. On a market cap of just ₹28 Cr, even a small profit recovery would matter, but at 33.14 times trailing earnings while profit fell 13.64%, the market is already paying for a turnaround. ROCE of 4.77% is far below what I would accept; I could get similar returns without the operational stress of speciality retail. The 15.26% sales growth is encouraging, but growth without profit does not create value. The Piotroski F-Score of 4/9 reinforces the picture of a financially fragile business. There is no dividend, so minority shareholders receive no return while waiting. With book value, debt-to-equity, promoter holding, and ROE not disclosed, I cannot judge balance-sheet risk or insider alignment. This fails my margin-of-safety test. A ₹28 Cr market cap leaves room for a small absolute turnaround, but I need evidence: consistent quarterly profit, improving ROCE, and clearer financial disclosures. Until then, this is a possible turnaround, not an investment. As Graham taught, price is what you pay; value is what you get. At ₹17.10 with zero latest-quarter earnings, I see little value. I would rather miss a speculative recovery than risk permanent capital in a business without a demonstrable moat.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer